{"id":946506,"date":"2026-03-24T10:24:55","date_gmt":"2026-03-24T14:24:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/"},"modified":"2026-03-24T10:24:55","modified_gmt":"2026-03-24T14:24:55","slug":"absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/","title":{"rendered":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic"},"content":{"rendered":"<h2>\nExperts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, Wash. and NEW YORK, March  24, 2026  (GLOBE NEWSWIRE) &#8212; Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,\u202f announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic.<\/p>\n<p align=\"justify\">Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an estimated 190 million worldwide. The current standard of care relies on hormonal therapies, GnRH agonists, and over-the-counter pain medications, none of which targets the underlying pathology driving the condition. The gap between patient need and available options underscores the urgency for a fundamentally different therapeutic approach.<\/p>\n<p align=\"justify\">ABS-201 is an anti-prolactin receptor (anti-PRLR) antibody designed to target a distinct, non-hormonal pathway in endometriosis. Prolactin receptor signaling is locally upregulated in ectopic endometrial tissue, where it drives inflammation and lesion survival independent of the hormonal suppression axis targeted by current therapies. By blocking this pathway, ABS-201 has the potential to treat endometriosis without suppressing ovulation or fertility\u2014a critical unmet need for the large population of patients of reproductive age. ABS-201 is formulated for subcutaneous self-administration with an extended half-life demonstrated in non-human primates, designed to support infrequent dosing and patient convenience outside of clinical settings.<\/p>\n<p align=\"justify\">\u201cToday, every approved endometriosis therapy works through hormonal suppression\u2014forcing patients to choose between managing their disease and preserving fertility. ABS-201 targets a fundamentally different pathway, and this Advisory Board of world-class leaders in reproductive medicine will help us design studies that demonstrate that differentiation where it matters most: in patient outcomes,\u201d said Sean McClain, Founder &amp; CEO of Absci. \u201cTheir guidance will be critical as we move toward Phase 2 initiation.\u201d<\/p>\n<p align=\"justify\">The formation of the ABS-201 Endometriosis Advisory Board marks a continued expansion of Absci\u2019s clinical expertise as the company advances its generative AI-designed therapeutic with an anticipated initiation of a Phase 2 study in endometriosis in the fourth quarter of 2026, and an interim data readout in the second half of 2027.<\/p>\n<p align=\"justify\">\n        <strong>About the Advisory Board<\/strong>\n      <\/p>\n<p align=\"justify\">The Absci endometriosis advisory board comprises leading clinician-scientists and industry experts spanning reproductive medicine, fertility, and translational research:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Hugh Taylor, MD<\/strong> \u2013 Anita O&#8217;Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology, Yale University and Chair, Obstetrics, Gynecology &amp; Reproductive Sciences; Chief, Obstetrics and Gynecology, Yale New Haven Hospital<\/li>\n<li style=\"text-align:justify\">\n          <strong>Linda Giudice, MD, PhD<\/strong> \u2013 Distinguished Professor, Chair Emerita, and Robert B. Jaffe MD Endowed Professor in the Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF)<\/li>\n<li style=\"text-align:justify\">\n          <strong>Gaurang Daftary, MD<\/strong> \u2013 Chief Scientific Officer and President of Physician Relations, Inception with over 20 years in women&#8217;s reproductive health across clinical, research, and industry leadership. Adjunct Associate Professor Yale University, Mayo Clinic<\/li>\n<li style=\"text-align:justify\">\n          <strong>Steven Young, MD<\/strong> \u2013 F. Bayard Carter Distinguished Professor of Obstetrics and Gynecology, Duke University<\/li>\n<li style=\"text-align:justify\">\n          <strong>Zaraq Khan, M.B.B.S<\/strong> \u2013 Assistant Professor, Mayo Clinic<\/li>\n<li style=\"text-align:justify\">\n          <strong>Joan-Carles Arce, MD<\/strong> \u2013 Chief Scientific and Medical Officer, Repronovo<\/li>\n<\/ul>\n<p align=\"justify\">\u201cFor many patients, endometriosis is chronic and life-disrupting, affecting daily function and fertility. I\u2019m glad to partner with Absci to help ensure ABS-201 is developed with the clinical rigor needed to evaluate its potential across this diverse disease,\u201d said Dr. Hugh Taylor.<\/p>\n<p align=\"justify\">\u201cEndometriosis presents in many ways, and patients benefit from an expanded set of treatment options that can be tailored across disease and life stages. I\u2019m pleased to collaborate with Absci and this Advisory Board as ABS-201 advances, with a focus on improving what\u2019s possible for patients,&#8221; said Dr. Linda Giudice.<\/p>\n<p align=\"justify\">\u201cWhat excites me about ABS-201 is the opportunity to help bring a new class of therapy into a field that has seen too little innovation for too long. Absci is taking a purposeful approach\u2014combining modern biologics development with a focus on patient impact\u2014and I\u2019m thrilled to contribute to work that could open new possibilities for people living with endometriosis,\u201d said Dr. Gaurang Daftary.<\/p>\n<p align=\"justify\">The Advisory Board will support study design, clinical strategy, and patient-informed endpoints as Absci advances ABS-201 in endometriosis.<\/p>\n<p align=\"justify\">\n        <strong>About Absci<\/strong><br \/>\n        <br \/>Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation\u2122 platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci\u2019s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential \u201cbest-in-class\u201d therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.<\/p>\n<p align=\"justify\">Absci\u00ae standard character mark, ABS-201\u2122, and Headline\u2122 are trademarks and registered trademarks of Absci Corporation.<\/p>\n<p align=\"justify\">\n        <strong>Absci Forward Looking Statements<\/strong><br \/>\n        <br \/>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) Absci\u2019s preclinical studies, clinical trials, as well as partnered and internally developed programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; (iii) Absci\u2019s strategy, goals, anticipated financial performance and the sufficiency of its cash resources; (iv) regulatory submissions and authorizations, including timelines for and expectations regarding any anticipated regulatory agency decisions; (v) the expected benefits of its collaborations with partners; and (vi) the therapeutic value, development, and commercial potential of antibody therapies, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading \u201cRisk Factors\u201d in Absci Corporation\u2019s most recent annual report on Form 10-K and in any other subsequent filings made by Absci Corporation with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>press@absci.com <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander D.H. Khan<br \/>Corporate Vice President<br \/>Head of Investor Relations<br \/>investors@absci.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWRjMzc2NDItYTI3Yi00MmEyLWJkYTAtMjgyYjJmNzAzZDk1LTEyMjE2MzMtMjAyNi0wMy0yNC1lbg==\/tiny\/ABSCI-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,\u202f announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an estimated 190 million worldwide. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946506","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,\u202f announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an estimated 190 million worldwide. The &hellip; Continue reading &quot;Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:24:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic\",\"datePublished\":\"2026-03-24T14:24:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/\"},\"wordCount\":1252,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/\",\"name\":\"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\",\"datePublished\":\"2026-03-24T14:24:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/","og_locale":"en_US","og_type":"article","og_title":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk","og_description":"Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic antibody treatment VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) &#8212; Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,\u202f announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an estimated 190 million worldwide. The &hellip; Continue reading \"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-24T14:24:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic","datePublished":"2026-03-24T14:24:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/"},"wordCount":1252,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/","name":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=","datePublished":"2026-03-24T14:24:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjkyNyM3NDk5MTYyIzIyMTAwODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946506"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946506\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}